<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04123418</url>
  </required_header>
  <id_info>
    <org_study_id>CWVT078A12101</org_study_id>
    <nct_id>NCT04123418</nct_id>
  </id_info>
  <brief_title>A Study of WVT078 in Patients With Multiple Myeloma (MM)</brief_title>
  <official_title>A Phase I, Open-label, Multicenter, Study of WVT078 in Subjects With Relapsed and/or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The design of a phase I, open-label, dose finding study was chosen in order to establish a&#xD;
      safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in&#xD;
      patients relapses and/or refractory Multiple Myeloma (MM)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This first-in-human trial with WVT078 is a dose escalation study whose primary purpose is to&#xD;
      characterize the safety, tolerability, and determine recommended dose regimen(s) of WVT078&#xD;
      alone and in combination with WHG626 in subjects with MM who have received two or more&#xD;
      standard of care lines of therapy including an IMID, a proteasome inhibitor, and an anti-CD38&#xD;
      agent (if available) and are relapsed and/or refractory to or intolerant of each regimen. In&#xD;
      addition, this study will assess preliminary anti-MM response of and characterize the&#xD;
      pharmacokinetics and immunogenicity of WVT078 alone and in combination with WHG626. The&#xD;
      results of this study will inform the future development of WVT078 alone and in combination&#xD;
      with WHG626 as a treatment for relapsed and/or refractory MM.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2019</start_date>
  <completion_date type="Anticipated">December 8, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 7, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicity (DLTs) in Cycle 1</measure>
    <time_frame>28 days (first cycle)</time_frame>
    <description>To characterize the safety, tolerability, and determine the recommended dose regimen(s) of WVT078 alone and in combination with WHG626 in subjects with relapsed and/or refractory MM</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of dose interruptions</measure>
    <time_frame>Up to 28 months</time_frame>
    <description>To characterize the safety, tolerability, and determine the recommended dose regimen(s) of WVT078 alone and in combination with WHG626 in subjects with relapsed and/or refractory MM</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of discontinuations</measure>
    <time_frame>up to 28 months</time_frame>
    <description>To characterize the safety, tolerability, and determine the recommended dose regimen(s) of WVT078 alone and in combination with WHG626 in subjects with relapsed and/or refractory MM</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of dose reductions</measure>
    <time_frame>up to 28 months</time_frame>
    <description>To characterize the safety, tolerability, and determine the recommended dose regimen(s) of WVT078 alone and in combination with WHG626 in subjects with relapsed and/or refractory MM</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of AEs and SAEs, including changes in laboratory values, vital signs, ECGs, and CRS/immune-mediated reactions</measure>
    <time_frame>Up to 31 months</time_frame>
    <description>To characterize the safety, tolerability, and determine the recommended dose regimen(s) of WVT078 alone and in combination with WHG626 in subjects with relapsed and/or refractory MM</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Response assessment per International Myeloma Working Group (IMWG) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Response assessment per International Myeloma Working Group (IMWG) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progresson Free Survival (PFS)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Response assessment per International Myeloma Working Group (IMWG) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of WVT078 derived from serum concentrations</measure>
    <time_frame>Up to 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of WVT078 derived from serum concentrations</measure>
    <time_frame>Up to 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin of WVT078 derived from serum concentrations</measure>
    <time_frame>Up to 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of WVT078 derived from serum concentrations</measure>
    <time_frame>Up to 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of WVT078 derived from serum concentrations</measure>
    <time_frame>Up to 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of WVT078 Anti Drug Antibodies (ADA) as measured in serum</measure>
    <time_frame>Up to 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of WHG626 derived from plasma concentrations</measure>
    <time_frame>Up to 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of WHG626 derived from plasma concentrations</measure>
    <time_frame>Up to 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin of WHG626 derived from plasma concentrations</measure>
    <time_frame>Up to 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of WHG626 derived from plasma concentrations</measure>
    <time_frame>Up to 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of WHG626 derived from plasma concentrations</measure>
    <time_frame>Up to 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of GWQ573 (the active metabolite of WHG626) derived from plasma concentrations</measure>
    <time_frame>Up to 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of GWQ573 (the active metabolite of WHG626) derived from plasma concentrations</measure>
    <time_frame>Up to 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin of GWQ573 (the active metabolite of WHG626) devived from plasma concentrations</measure>
    <time_frame>Up to 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of GWQ573 (the active metabolite of WHG626) derived from plasma concentrations</measure>
    <time_frame>Up to 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of GWQ573 (the active metabolite of WHG626) derived from plasma concentrations</measure>
    <time_frame>Up to 28 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Multiple Myeloma (MM)</condition>
  <arm_group>
    <arm_group_label>WVT078 in Multiple Myeloma (MM) patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation study to determine Maximum Tolerated Dose (MTD)/ Recommended Dose (RD) in adult patients with relapsed and/or refractory Multiple Myeloma (MM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WVT078 in combination with WHG626 in Multiple Myeloma (MM) patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation study to determine Maximum Tolerated Dose (MTD)/ Recommended Dose (RD) in adult patients with relapsed and/or refractory Multiple Myeloma (MM)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>WVT078</intervention_name>
    <description>WVT078 will be administered IV (intravenously) in a dose escalation schedule</description>
    <arm_group_label>WVT078 in Multiple Myeloma (MM) patients</arm_group_label>
    <arm_group_label>WVT078 in combination with WHG626 in Multiple Myeloma (MM) patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WHG626</intervention_name>
    <description>WHG626 will be administered orally in a dose escalation schedule</description>
    <arm_group_label>WVT078 in combination with WHG626 in Multiple Myeloma (MM) patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who are relapsed and/or refractory to two or more regimens including an IMID,&#xD;
             proteasome inhibitor, and an anti-CD38 agent (if available)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of systemic chronic steroid therapy (&gt;or= 10mg/day prednisone or equivalent) or&#xD;
             any immunosuppressive therapy within 7 days of first dose of study treatment&#xD;
&#xD;
          -  Malignant disease other than being treated on this study&#xD;
&#xD;
          -  Active known or suspected autoimmune disease&#xD;
&#xD;
          -  Impaired cardiac function or clinically significant cardiac disease&#xD;
&#xD;
          -  Treatment with cytotoxic or small molecule antineoplastics or any experimental therapy&#xD;
             within 14 days or 5 half-lives whichever is shorter&#xD;
&#xD;
          -  Active central nervous system involvement by malignancy or presence of symptomatic CNS&#xD;
             metasteses&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cicely Kanayo Flood</last_name>
      <phone>+1 404 778 4189</phone>
      <email>cicely.patrice.flood@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan L. Kaufman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>507-538-2155</phone>
    </contact>
    <investigator>
      <last_name>Rahma Warsame</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samanike Hengst</last_name>
      <phone>608-262-7202</phone>
      <email>shengst@wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Natalie Callander</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Althea B Thomas</last_name>
      <phone>414-805-5249</phone>
      <email>Athomas@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Parameswaran Hari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prahran</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo ku</city>
        <state>Tokyo</state>
        <zip>113-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oslo</city>
        <zip>NO 0450</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 2, 2019</study_first_submitted>
  <study_first_submitted_qc>October 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2019</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma, phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

